Intranasal administration of human lactoferrin in the transgenic mouse model of AD (APPswe/PS1DE9) has been shown to promote the non-amyloidogenic metabolism of APP processing through activation of α-secretase and ADAM10, leading to the production of soluble form of APP, sAPPα, having a neuroprotective role. Here, LTF is linked to Alzheimer disease.